Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: A review of pathophysiology, mechanisms, and evidence from recent trials
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: A review of pathophysiology, mechanisms, and evidence from recent trials
Authors
Keywords
-
Journal
DIABETES OBESITY & METABOLISM
Volume 24, Issue 3, Pages 365-376
Publisher
Wiley
Online
2021-11-15
DOI
10.1111/dom.14601
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and durability of multifactorial intervention on mortality and MACEs: a randomized clinical trial in type-2 diabetic kidney disease
- (2021) Ferdinando Carlo Sasso et al. Cardiovascular Diabetology
- Chronic kidney disease
- (2021) Kamyar Kalantar-Zadeh et al. LANCET
- Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial
- (2020) Nete Tofte et al. Lancet Diabetes & Endocrinology
- The Unrecognized Prevalence of Primary Aldosteronism
- (2020) Jenifer M. Brown et al. ANNALS OF INTERNAL MEDICINE
- Aldosterone, Inflammation, Immune System, and Hypertension
- (2020) Nathanne S Ferreira et al. AMERICAN JOURNAL OF HYPERTENSION
- Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose–response study and open-label extension study
- (2020) Takashi Wada et al. Clinical and Experimental Nephrology
- Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
- (2020) Rajiv Agarwal et al. EUROPEAN HEART JOURNAL
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
- (2020) George L. Bakris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Autophagy in Chronic Kidney Diseases
- (2019) Tien-An Lin et al. Cells
- Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis
- (2019) Jonatan Barrera-Chimal et al. KIDNEY INTERNATIONAL
- Absolute Bioavailability of Esaxerenone and Food Effects on its Pharmacokinetics After a Single Oral Dose in Healthy Japanese Subjects: An Open-Label Crossover Study
- (2019) Akifumi Kurata et al. ADVANCES IN THERAPY
- Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
- (2019) Hiddo J L Heerspink et al. LANCET
- A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes
- (2019) Monika A. Niewczas et al. NATURE MEDICINE
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria
- (2019) Sadayoshi Ito et al. Clinical Journal of the American Society of Nephrology
- Unraveling the Role of Inflammation in the Pathogenesis of Diabetic Kidney Disease
- (2019) Keiichiro Matoba et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Does the temporary decrease in the estimated glomerular filtration rate (eGFR) after initiation of mineralocorticoid receptor (MR) antagonist treatment lead to a long-term renal protective effect?
- (2019) Atsuhisa Sato HYPERTENSION RESEARCH
- Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment
- (2019) Akifumi Kurata et al. ADVANCES IN THERAPY
- The new biology of diabetic kidney disease - mechanisms and therapeutic implications
- (2019) Yuliya Lytvyn et al. ENDOCRINE REVIEWS
- 11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes−2020
- (2019) DIABETES CARE
- Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease
- (2018) Radica Z. Alicic et al. ADVANCES IN CHRONIC KIDNEY DISEASE
- Galectin-3 is independently associated with progression of nephropathy in type 2 diabetes mellitus
- (2018) Kathryn C. B. Tan et al. DIABETOLOGIA
- Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone’s Antifibrotic ActivityNovelty and Significance
- (2018) Jana Grune et al. HYPERTENSION
- Update of pathophysiology and management of diabetic kidney disease
- (2018) Yi-Chih Lin et al. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
- Sodium glucose cotransporter 2 inhibition and renal ischemia: implications for future clinical trials
- (2018) Daniël H. van Raalte et al. KIDNEY INTERNATIONAL
- Pharmacokinetics, Metabolism, and Excretion of [14C]Esaxerenone, a Novel Mineralocorticoid Receptor Blocker in Humans
- (2018) Makiko Yamada et al. DRUG METABOLISM AND DISPOSITION
- SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy
- (2017) Xiaoxin X. Wang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy
- (2017) Shigehiro Katayama et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment
- (2017) Lennart Tonneijck et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and/or Chronic Kidney Disease
- (2016) Naoki Sato et al. CIRCULATION JOURNAL
- Cardiac Tissue Injury and Remodeling Is Dependent Upon MR Regulation of Activation Pathways in Cardiac Tissue Macrophages
- (2016) Jimmy Z. Shen et al. ENDOCRINOLOGY
- A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
- (2016) Gerasimos Filippatos et al. EUROPEAN HEART JOURNAL
- Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists Cause Differential Cardiac Gene Expression in Pressure Overload-induced Cardiac Hypertrophy
- (2016) Jana Grune et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Mineralocorticoid regulation of cell function: the role of rapid signalling and gene transcription pathways
- (2016) Gregory S Y Ong et al. JOURNAL OF MOLECULAR ENDOCRINOLOGY
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist
- (2015) Kiyoshi Arai et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Adipocyte Mineralocorticoid Receptor Activation Leads to Metabolic Syndrome and Induction of Prostaglandin D2 SynthaseNovelty and Significance
- (2015) Riccardo Urbanet et al. HYPERTENSION
- Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy
- (2015) George L. Bakris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1
- (2015) Larbi Amazit et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury
- (2014) Peter Kolkhof et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Diabetic kidney disease: from physiology to therapeutics
- (2014) Carmen Mora-Fernández et al. JOURNAL OF PHYSIOLOGY-LONDON
- Role of the endothelial-to-mesenchymal transition in renal fibrosis of chronic kidney disease
- (2013) Jianhua He et al. Clinical and Experimental Nephrology
- Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
- (2013) Bertram Pitt et al. EUROPEAN HEART JOURNAL
- Kidney Disease and Increased Mortality Risk in Type 2 Diabetes
- (2013) M. Afkarian et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease
- (2012) Bertram Pitt et al. EUROPEAN JOURNAL OF HEART FAILURE
- Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease
- (2011) Jean-Philippe Bertocchio et al. KIDNEY INTERNATIONAL
- Oxidative Stress and Diabetic Complications
- (2010) Ferdinando Giacco et al. CIRCULATION RESEARCH
- FGF-23 as a Predictor of Renal Outcome in Diabetic Nephropathy
- (2010) S. M. Titan et al. Clinical Journal of the American Society of Nephrology
- Chronic Kidney Disease and the Risk of End-Stage Renal Disease versus Death
- (2010) Lorien S. Dalrymple et al. JOURNAL OF GENERAL INTERNAL MEDICINE
- The role of 11β-hydroxysteroid dehydrogenase type 2 in human hypertension
- (2009) Paolo Ferrari BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Treating Elderly People with Diabetes and Stages 3 and 4 Chronic Kidney Disease
- (2008) C. Abaterusso et al. Clinical Journal of the American Society of Nephrology
- Local renal aldosterone production induces inflammation and matrix formation in kidneys of diabetic rats
- (2008) Helmy M. Siragy et al. EXPERIMENTAL PHYSIOLOGY
- Activation of the renal renin-angiotensin system in diabetes--new concepts
- (2008) J. Peti-Peterdi et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started